| Pronunciation |
 (dye
men HYE dri
nate) |
 |
| U.S. Brand Names |
| Calm-X® Oral [OTC]; Dimetabs® Oral; Dinate® Injection; Dramamine® Oral [OTC]; Dymenate® Injection; Hydrate® Injection; TripTone® Caplets®[OTC] |
|
| Generic Available |
|
Yes |
|
| Pharmacological Index |
|
Antihistamine |
|
| Use |
|
Treatment and prevention of nausea, vertigo, and vomiting associated with motion sickness |
|
| Pregnancy Risk Factor |
|
B |
|
| Contraindications |
|
Hypersensitivity to dimenhydrinate or any component |
|
| Adverse Reactions |
|
>10%: Central nervous system: Slight to moderate drowsiness Respiratory: Thickening of bronchial secretions 1% to 10%: Central nervous system: Headache, fatigue, nervousness, dizziness Gastrointestinal: Appetite increase, weight increase, nausea, diarrhea, abdominal pain, xerostomia Neuromuscular & skeletal: Arthralgia Respiratory: Pharyngitis |
|
| Drug Interactions |
|
Increased effect/toxicity with CNS depressants, anticholinergics, TCAs, MAO inhibitors Increased toxicity of antibiotics, especially aminoglycosides (ototoxicity) |
|
| Stability |
|
When mixed in the same syringe, drugs reported to be incompatible include aminophylline, barbiturates, butorphanol, chlorpromazine, glycopyrrolate, heparin, hydrocortisone, hydroxyzine, midazolam, phenytoin, prednisolone, prochlorperazine, promethazine, tetracycline, trifluoperazine |
|
| Mechanism of Action |
|
Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract; blocks chemoreceptor trigger zone, diminishes vestibular stimulation, and depresses labyrinthine function through its central anticholinergic activity |
|
| Pharmacodynamics/Kinetics |
|
Onset of action: Oral: Within 15-30 minutes Absorption: Well absorbed from GI tract |
|
| Usual Dosage |
|
Children: Oral: 2-5 years: 12.5-25 mg every 6-8 hours, maximum: 75 mg/day 6-12 years: 25-50 mg every 6-8 hours, maximum: 150 mg/day I.M.: 1.25 mg/kg or 37.5 mg/m2 4 times/day, not to exceed 300 mg/day Adults: Oral, I.M., I.V.: 50-100 mg every 4-6 hours, not to exceed 400 mg/day |
|
| Dietary Considerations |
|
May be administered with food or water |
|
| Administration |
|
I.V. injection must be diluted to 10 mL with normal saline and given at 25 mg/minute |
|
| Mental Health: Effects on Mental Status |
|
Drowsiness is common; may cause depression, nervousness, or paradoxical CNS stimulation |
|
| Mental Health: Effects on Psychiatric Treatment |
|
Concurrent use with psychotropic may result in additive sedation |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
Up to 10% of patients will complain of significant dry mouth and drowsiness. This will disappear with cessation of drug therapy. |
|
| Patient Information |
|
May cause drowsiness, may impair judgment and coordination; avoid alcohol; drink plenty of fluids for dry mouth and to prevent constipation |
|
| Dosage Forms |
|
Capsule: 50 mg Injection: 50 mg/mL (1 mL, 5 mL, 10 mL) Liquid: 12.5 mg/4 mL (90 mL, 473 mL); 16.62 mg/5 mL (480 mL) Tablet: 50 mg Chewable: 50 mg |
|
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
